NEUTRAL / RISK-OFF Wednesday's U.S. rebound and calmer futures are offset by a 4.79% 10-year yield, war-driven energy risk, record gold and sharp expectation resets in high-multiple AI.
Generated 08:35:14 CEST (Europe/Rome) / 06:35:14 UTC. Data cutoff about 08:31 CEST. U.S. and European cash values are Sep. 2 closes; Asian values are Sep. 3 latest/near-close; futures/commodities are overnight observations around 08:23 CEST. At 08:30 Italy, European cash markets are not yet open and U.S. cash trading/many U.S. releases are hours away.
Cash changes use adjacent daily closes. Futures/commodities compare the current session observation with the prior daily settlement bar; values are indicative and can move before the open. Official Treasury curve is dated Sep. 2.
All four U.S. cash indices rose and Russell led, while VIX eased. Yet PLTR fell 5.81%, CRDO another 20.04%, and Europe/Asia were mostly soft. This is stabilization, not a clean risk-on confirmation. S&P data · Russell · CRDO
The official curve held 2Y/10Y at 4.39%/4.79%. CNBC reports Kuwait defending against Iranian missile/drone attacks and a continuing global bond rout. WTI eased overnight but remains near $90; gold jumped 2.32%. Treasury · CNBC · gold
Broadcom reported Q3 revenue +86% YoY and AI-semiconductor revenue +221%; HPE raised outlook; Snowflake raised FY product-revenue guidance. Nonetheless AVGO closed −0.66% before results and SNOW −4.37%, while NVDA +3.21% led. Results validate demand, but not every valuation. AVGO release · HPE release · SNOW release
Risk class: mega-cap semiconductor, high expectations. Classification: momentum repair/relative strength. Applicable horizon: day trade and 1–4 week swing after confirmation; 3–12+ months only with valuation/FCF discipline. Direction uncertain.
Thesis/catalyst: $224.41, +3.21% on 156.7M shares, reclaimed the prior $220.41 confirmation and outperformed Nasdaq. Existing company evidence includes Q2 revenue $46.7B and Q3 revenue guide $54.0B ±2%; AVGO/HPE results corroborate infrastructure demand.
Evidence / counterargument: close was above Monday/Tuesday highs and volume expanded. Counter: Wednesday reversed from $227.95, yields remain high, export/customer concentration and capex digestion can compress the multiple.
Entry/confirmation: require hold above $220.41 and a break/close above $227.95 with semiconductor breadth. Invalidation/downside: close below $218.48 weakens; below $215.10 invalidates repair, with $209.23 reference. Key risks: valuation, margins, China/export policy, customer concentration, competition, power constraints and market rates. company results · price/volume
Risk class: large-cap enterprise infrastructure; earnings/integration volatility. Classification: fundamental acceleration with price confirmation pending. Applicable horizon: day and 1–4 weeks after breakout; 3–12+ months after Juniper integration, leverage and FCF review. Direction uncertain.
Thesis/catalyst: $51.83, +1.89% on 60.2M shares before its official release. Q3 revenue hit $12.2B (+34%); data-center networking +112.2%, server +35.3%; FY26 and FY27 revenue/FCF outlooks were raised.
Evidence / counterargument: official FY27 framework calls for 13–17% revenue growth and at least $5.0B FCF. Counter: results arrived after cash close; the stock must price them, Juniper integration and debt/margin mix matter, and event gaps bypass levels.
Entry/confirmation: do not chase pre-market; require regular-session hold above $52.48 then $53.16 on volume. Invalidation/downside: close below $49.80 invalidates breakout structure; $48 is a secondary reference. Key risks: integration, leverage, component supply, AI-server margins, customer concentration, competition, guidance execution and rates. SEC-furnished release · price/volume
Risk class: high-beta AI connectivity; extreme post-earnings volatility, concentration and valuation risk. Classification: avoid-first; no blind short. Applicable horizon: day observation and 1–4 week base; 3–12+ months only after valuation, customer mix, margins and FCF review. Direction highly uncertain; short loss is unlimited.
Thesis/catalyst: $165.22, −20.04% on 29.9M shares; prior report's requirement to wait for cash price discovery was correct risk control. The gap followed Q1 FY27 revenue +114.7% YoY and continued despite robust sector evidence—clear expectation reset.
Evidence / counterargument: close near a $161.95 low and below the $190.57 high confirms sellers controlled the session. Counter: official Q2 revenue outlook $525–535M, strong growth and $764.3M cash/short investments can fuel a violent reversal.
Entry/confirmation: avoid; bearish only after failed reclaim of $171 then break below $161.95. Invalidation/downside: sustained reclaim above $190.57 invalidates; $150 is only a reference, not a target. Key risks: squeeze, gaps, liquidity, customer concentration, margins, guidance interpretation and rates; borrow/fees unknown. official release · price/volume
Risk class: large-cap, high-multiple AI software. Classification: avoid until base; tactical bearish only on failed reclaim. Applicable horizon: day and 1–4 weeks; no 3–12+ month short thesis without fresh valuation/fundamental work. Direction uncertain; short loss is unlimited.
Thesis/catalyst: $169.46, −5.81% on 39.7M shares while Nasdaq rose 0.45%; it lost the prior $179.75 low and printed $165.71. Relative-strength failure under a 4.79% 10Y is the evidence.
Evidence / counterargument: expanding volume and an intraday high only $177.57 show a failed reclaim. Counter: Wednesday bounced $3.75 from the low, strong AI demand can revive sentiment, and squeezes are possible.
Entry/confirmation: avoid; tactical bearish only on failed $173–177.57 reclaim then loss of $165.71. Invalidation/downside: close above $179.75 invalidates; $160/$155 are references, not forecasts. Key risks: contract/news catalyst, government concentration, valuation, rates, squeeze and unlimited short loss; borrow/fees unknown. price/volume · MarketWatch news feed
No third bullish or bearish setup: overnight futures are flat, macro event risk is elevated, and post-earnings price discovery is incomplete. Fewer, conditional ideas are preferable to filling quotas.
Risk class: mega-cap semiconductor/infrastructure; event-gap, leverage and concentration risk. Classification/horizon: direction uncertain; day/1–4 weeks only after post-report price discovery; 3–12+ months after valuation, debt and FCF review.
Thesis/catalyst/evidence: $367.24, −0.66% cash close. Official Q3 revenue $29.591B, FCF $13.665B and AI-semiconductor revenue $16.7B; Q4 AI expectation $21.7B. Counter: CNBC reports the $34.8B total-revenue guide below $35.03B LSEG consensus; expectations and customer concentration are high.
Confirmation: regular-session hold above $371.09 then $376.59. Invalidation/downside: below $364.65 weakens; $362/$355.31 references. Risks: customer concentration, networking/custom-silicon execution, VMware integration, debt, export controls and rates. release · price
Risk class: large-cap cloud software; consumption and valuation risk. Classification/horizon: direction uncertain, post-earnings reversal watch; day/1–4 weeks after stabilization; 3–12+ months requires GAAP profitability/SBC review.
Thesis/evidence: $305.84, −4.37% on 11.3M shares before results. Official Q2 product revenue +37%, RPO +30%, NRR 126%; FY27 product-revenue guide raised to $6.07B and non-GAAP operating-margin guide to 14.5%. Counter: GAAP operating loss was $263M, FCF margin 5.4%, and the chart closed near $303.89 low.
Confirmation: reclaim $319.25 then $319.80 on volume. Invalidation/downside: below $303.89 keeps trend weak; $295 reference. Risks: consumption variability, competition, SBC/dilution, convertible notes, valuation and rates. release · price
Risk class: large-cap/high-beta AI power and cooling. Classification/horizon: direction uncertain; consolidation watch for 1–4 weeks; 3–12+ months after backlog, margin and FCF review.
Thesis/evidence: $256.70, +0.29%, held $251.50 and remains tied to verified AI buildout. Counter: lagged NVDA/HPE and failed at $260.05; high rates and local opposition can delay data-center projects.
Confirmation: close above $260.05 then $261.79; stronger above $270. Invalidation/downside: below $251.50 weakens, below $248.75 invalidates. Risks: capex timing, execution, valuation, inputs, power availability, permitting and rates. price · construction pushback
Risk class: speculative quantum; extreme duration, dilution and capital-structure risk. Classification/horizon: direction uncertain; avoid-to-watch; day/1–4 weeks only after reclaim; 3–12+ months requires commercial/unit-economics proof.
Thesis/evidence: $37.64, −0.37%, lagged Russell; Sep. 29/30 warrant cessation/expiry is date-certain. Counter: intraday low $36.785 held and contract/technical news can reverse price sharply.
Confirmation: reclaim $38.24 then $39.25. Invalidation/downside: below $36.785 keeps no-long stance; $35 reference. Risks: cash burn, dilution/warrants, architecture, commercialization, rates and squeezes; borrow/fees unknown. 8-K · price
Risk class: large-cap peptide/metabolic pharma; pipeline, pricing and ADR/currency risk. Classification/horizon: direction uncertain; rebound watch for day/1–4 weeks; 3–12+ months needs pipeline, pricing and valuation review.
Thesis/evidence: $46.77, +3.66% on 13.6M shares, reclaimed $46.16. Counter: move remains only a bounce after a weak multi-day trend; no new primary catalyst was verified today and Lilly competition remains intense.
Confirmation: hold $45.91 and close above $47.01, stronger above $47.19. Invalidation/downside: below $45.91 weakens; below $45.07 invalidates. Risks: trial/safety, reimbursement, pricing, manufacturing, competition, currency and regulation. price/volume · competing retatrutide study
Confidence measures evidence quality, never guaranteed outcome probability. Risk is higher when riskier. Opportunity combines setup quality and risk; triggers are conditional, not claimed fills.
Bias: selective/defensive. Favor confirmed NVDA strength; let HPE/AVGO/SNOW establish cash-session ranges. Do not chase gaps or bottom-fish CRDO.
Biggest risk: Gulf/oil headline plus post-earnings gaps. Invalidation: caution eases if ES/NQ rise with Russell/semiconductor breadth and 10Y retreats; it worsens if ES loses 7,661 and WTI reclaims $91.46.
Bias: modest risk, conditional. NVDA/HPE only above confirmations; keep quantum avoid-first and demand bases in CRDO/PLTR.
Biggest risk: jobs/CPI/FOMC reprice yields upward. Invalidation: a 10Y break below 4.70% plus broad, volume-backed participation would support more growth exposure; renewed 4.80%+ pressure argues cash-heavy.
Bias: favor profitable AI infrastructure after valuation/FCF work; require commercial proof in quantum and complete clinical/runway evidence in biotech.
Biggest risk: persistent inflation, capex digestion, customer concentration, dilution or failed endpoints. Invalidation: durable disinflation plus verified order, margin and FCF acceleration supports more duration.